Clinical Research Experience


We focus on phases II & III clinical trials. Therapeutic areas are Alzheimer's Disease,  Epilepsy, Migraine Headaches, Multiple Sclerosis Diabetic Neuropathic Pain and Stroke. Our investigators have successfully been conducting studies with the following pharmaceutical companies:
 
 

 Alzheimer’s Disease

Sponsor Drug Name Phase Protocol Enrollment Commitment Completed Patients
Eli Lilly Olanzepine II FID-US-HGIC-008 10 08
Janssen Galantamine III GAI-USA-10-18 63 55
Neurochem Alzhemed III CL-758007 12 23
Novartis Exelon III CENA713BUS13 08 11
ONO N/A II ONO-2506 08 08
Bayer Metrifonate IIII N/A 08 06
Parke-Davis Milameline III N/A 12 10
Hoechst Mentane III N/A 10 08


 Migraine Headaches

Sponsor Drug Name Phase Protocol Enrollment Commitment Completed Patients
J&J PRI Topamax III MIG-002 08 15
AstraZeneca Zomig III 311CUS/0022 10 12
GSK Sumatriptan III SUM40299 08 09
ZICAM MTX-M3 III MTX-M3 10 10

 Epilepsy
 
Sponsor Drug Name Phase Protocol Enrollment Commitment Completed Patients
J&J Pri Topamax III EPMN-106 10 06
Élan Zonegran III AN46046-304 06 09
GSK Lamictal III LAM40124 06 03

 Multiple Sclerosis
 
Sponsor Drug Name Phase Protocol Enrollment Commitment Completed Patients
Teva Copaxone II Copolymer 10 06
Peptimmune Cytokine II MS-001 20 24
Biogen BG-12 Define III 109-MS-303 06 04
Biogen BG-12 Endorse III 109-MS-303 02 02
Novartis Gilenya IIII CFTY720DUS01 06 04

 Diabetic Neuropathic Pain
 
Sponsor Drug Name Phase Protocol Enrollment Commitment Completed Patients
J&J PRD Topamax III NP-001 10 07
Sankyo Fidaristat II SNK-860-201 06 03

 Stroke
 
Sponsor Drug Name Phase Protocol Enrollment Commitment Completed Patients
Park-Davis Fosphenytoin II N/A 10 08
ONO ONO-2506 II ONO-2506 08 06
BMS N/A II N/A 10 07
Yamanuchi YM-872 II YM-872 06 04

 

BackBack to top

 © CNS Research, Inc.                                                                                                                              Contact: (800) 707-6013 Email: info@cns-research.com